Biomedical Journal of Scientific & Technical Research最新文献

英文中文

Immunomodulatory Strategies for Spinal Cord Injury. 脊髓损伤的免疫调节策略。

Biomedical Journal of Scientific & Technical Research

Pub Date : 2022-07-01 DOI: 10.26717/bjstr.2022.45.007202

Jonghyuck Park

Neuroinflammation is a key secondary event after spinal cord injury (SCI) and can increase barriers to regeneration, leading to various neurological disorders. Infiltrated hematogenous innate immune cells into the injured site are considered the main effector cells of the inflammatory responses after SCI. Glucocorticoids were the standard of care for spinal cord trauma for years due to their anti-inflammatory properties yet were also associated with unwanted side effects. While the administration of glucocorticoids is controversial, immunomodulatory strategies that limit inflammatory responses provide the potential therapeutic approaches to promote functional regeneration following SCI. Herein, we will discuss emerging therapeutic strategies to modulate inflammatory responses to enhance nerve recovery after spinal cord trauma.

神经炎症是脊髓损伤(SCI)后重要的继发性事件，可增加再生障碍，导致各种神经系统疾病。浸润到损伤部位的造血先天免疫细胞被认为是脊髓损伤后炎症反应的主要效应细胞。由于其抗炎特性，糖皮质激素多年来一直是脊髓创伤的标准治疗方法，但也与不良副作用有关。虽然糖皮质激素的使用存在争议，但限制炎症反应的免疫调节策略为促进脊髓损伤后的功能再生提供了潜在的治疗方法。在这里，我们将讨论新兴的治疗策略来调节炎症反应，以增强脊髓创伤后神经的恢复。

引用次数: 0

A Case of Thoracic Disc Herniation Effectively Treated with Interventional Radiology Computed Tomography- Guided Percutaneous Endoscopic Radiofrequency Annuloplasty Using a Disc-Fx® 介入放射学计算机断层引导下经皮内镜下射频环成形术治疗胸椎间盘突出症1例

Biomedical Journal of Scientific & Technical Research

Pub Date : 2022-02-04 DOI: 10.26717/bjstr.2022.41.006636

Takayuki Kobayashi

a for whom Interventional Radiology-Computed Tomography (IVR-CT)-guided Percutaneous Endoscopic Radiofrequency Annuloplasty (PERA) performed for the thoracic disc herniation to reduce the incidence of complications and improve treatment results, leading to a favorable outcome

a介入放射-计算机断层扫描(IVR-CT)引导下经皮内镜射频环成形术(PERA)治疗胸椎间盘突出症，减少了并发症的发生率，改善了治疗效果，取得了良好的结果

引用次数: 0

COVID-19 and Human Immune System Responses COVID-19与人体免疫系统反应

Biomedical Journal of Scientific & Technical Research

Pub Date : 2022-02-03 DOI: 10.26717/bjstr.2022.41.006633

Sylvia Smart

Sylvia Smart. COVID-19 and Human Immune System Responses. Biomed

西尔维娅聪明。COVID-19与人体免疫系统反应。生物医学

引用次数: 0

Stress Prevalence in College Students During COVID-19 Pandemics: Evidence from Economics Undergraduates in a Developing Country COVID-19大流行期间大学生的压力流行:来自发展中国家经济学本科生的证据

Biomedical Journal of Scientific & Technical Research

Pub Date : 2022-02-02 DOI: 10.26717/bjstr.2022.41.006624

Jorge Trevino

引用次数: 0

Pore Characterization of Alumina Short Fiber Using Small Angle X-Ray Scattering Technique 利用小角x射线散射技术表征氧化铝短纤维的孔隙结构

Biomedical Journal of Scientific & Technical Research

Pub Date : 2022-02-02 DOI: 10.26717/bjstr.2022.41.006622

H. Yazid

引用次数: 0

Value of BI-RADS 3 Audits. BI-RADS 3审计值。

Biomedical Journal of Scientific & Technical Research

Pub Date : 2022-02-01 DOI: 10.26717/BJSTR.2022.41.006668

Prithwijit Roychowdhury, Gopal R Vijayaraghavan, John Roubil, Imani M Williams, Efaza Siddiqui, Srinivasan Vedantham

Objectives: BI-RADS 3 is an established assessment category in which the probability of malignancy is equal to or less than 2%. However, monitoring adherence to imaging criteria can be challenging and there are few established benchmarks for auditing BI-RADS 3 assignments. In this study, we explore some parameters that could serve as useful tools for quality control and clinical practice management.

Materials and methods: This retrospective study covered a 4-year period (Jan 2014-Dec 2017) and included all women over 40 years who were recalled from a screening exam and had an initial assignment of BI-RADS 3 (probably benign) category after diagnostic workup. A follow-up period of 2 years following the assignment of BI-RADS 3 was used for quantitative quality control metrics.

Results: Among 135,765 screening exams, 13,453 were recalled and 1,037 BI-RADS 3 cases met inclusion criteria. The follow-up rate at 24 months was 86.7%. The upgrade rate was 7.4% (77/1,037) [CI: 5.9-9.2%] and the PPV3 was 33.8% (26/77) [CI: 23.4-45.5%]. The cancer yield was 2.51% (26/1,037) [CI: 1.64-3.65%] and did not differ (p=0. 243) from the 2% probability of malignancy. The initial BI-RADS3 per screening exam and per recall from screening were 0.76% (1,037/135,765) [CI: 0.72-0.81%] and 7.7% (1,037/13,453) [CI: 7.26-8.17%], respectively.

Conclusion: Regular audit of BIRADS 3 metrics has the potential to provide additional insights for clinical practice management. Data from varied clinical settings with input from an expert committee could help establish benchmarks for these metrics.

目的:BI-RADS 3是一个既定的评估类别，其中恶性肿瘤的概率等于或小于2%。然而，监测成像标准的依从性是具有挑战性的，并且很少有既定的基准来审计BI-RADS 3任务。在本研究中，我们探讨了一些参数可以作为质量控制和临床实践管理的有用工具。材料和方法:这项回顾性研究涵盖了4年(2014年1月- 2017年12月)，包括所有40岁以上的女性，她们从筛查检查中被召回，在诊断检查后被初始分配为BI-RADS 3(可能是良性的)类别。在BI-RADS 3分配后的2年随访期用于定量质量控制指标。结果:135,765例筛查检查中，召回13,453例，1037例BI-RADS 3符合纳入标准。24个月随访率为86.7%。升级率为7.4% (77/ 1037)[CI: 5.9-9.2%]， PPV3为33.8% (26/77)[CI: 23.4-45.5%]。两组的肿瘤发生率为2.51% (26/ 1037)[CI: 1.64-3.65%]，差异无统计学意义(p= 0.05)。243)从2%的恶性概率。每次筛查检查和每次筛查召回的初始BI-RADS3分别为0.76% (1,037/135,765)[CI: 0.72-0.81%]和7.7% (1,037/13,453)[CI: 7.26-8.17%]。结论:定期审核BIRADS 3指标有可能为临床实践管理提供额外的见解。来自不同临床环境的数据以及专家委员会的输入可以帮助建立这些指标的基准。

{"title":"Value of BI-RADS 3 Audits.","authors":"Prithwijit Roychowdhury, Gopal R Vijayaraghavan, John Roubil, Imani M Williams, Efaza Siddiqui, Srinivasan Vedantham","doi":"10.26717/BJSTR.2022.41.006668","DOIUrl":"https://doi.org/10.26717/BJSTR.2022.41.006668","url":null,"abstract":"Objectives: BI-RADS 3 is an established assessment category in which the probability of malignancy is equal to or less than 2%. However, monitoring adherence to imaging criteria can be challenging and there are few established benchmarks for auditing BI-RADS 3 assignments. In this study, we explore some parameters that could serve as useful tools for quality control and clinical practice management.Materials and methods: This retrospective study covered a 4-year period (Jan 2014-Dec 2017) and included all women over 40 years who were recalled from a screening exam and had an initial assignment of BI-RADS 3 (probably benign) category after diagnostic workup. A follow-up period of 2 years following the assignment of BI-RADS 3 was used for quantitative quality control metrics.Results: Among 135,765 screening exams, 13,453 were recalled and 1,037 BI-RADS 3 cases met inclusion criteria. The follow-up rate at 24 months was 86.7%. The upgrade rate was 7.4% (77/1,037) [CI: 5.9-9.2%] and the PPV3 was 33.8% (26/77) [CI: 23.4-45.5%]. The cancer yield was 2.51% (26/1,037) [CI: 1.64-3.65%] and did not differ (p=0. 243) from the 2% probability of malignancy. The initial BI-RADS3 per screening exam and per recall from screening were 0.76% (1,037/135,765) [CI: 0.72-0.81%] and 7.7% (1,037/13,453) [CI: 7.26-8.17%], respectively.Conclusion: Regular audit of BIRADS 3 metrics has the potential to provide additional insights for clinical practice management. Data from varied clinical settings with input from an expert committee could help establish benchmarks for these metrics.","PeriodicalId":9035,"journal":{"name":"Biomedical Journal of Scientific & Technical Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983005/pdf/nihms-1790042.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10711605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

SNP Genotyping Enhancements: From Traditional PCR to Double Helix Structural Oligonucleotides (STexS) SNP基因分型增强:从传统PCR到双螺旋结构寡核苷酸(STexS)

Biomedical Journal of Scientific & Technical Research

Pub Date : 2022-01-26 DOI: 10.26717/bjstr.2022.41.006585

Hyoung Min Park

引用次数: 0

Tumors Originating from Fat Tissue in the Head and Neck Area: A Review of 40 Cases 头颈部脂肪源性肿瘤40例临床分析

Biomedical Journal of Scientific & Technical Research

Pub Date : 2022-01-26 DOI: 10.26717/bjstr.2022.41.006589

Atsushi Ochiai

Originating from Fat Tissue in the Head and Neck Area: A Cases. Prognosis Objectives: To clarify the features of lipomas that had been operated on in Kitasato University Hospital (KUH) and diagnosed by reviewing a series of cases. Method: All patients having undergone tumor removal between January 2000 and December 2021. Patients were identified through pathology department records. Results: Ages ranged from 2 to 80 years, with an average age of 47.1 years. Lipomas were benign in 38 cases and malignant in 2 cases. All 38 lipomas required only surgery. In cases of lipoma, 3 cases developed complications after surgery. In the cases of lipoma, although postoperative results were varied and changing, there were no recurrences. Conclusion: Clinical files were reviewed for 40 patients. Lipomas were benign in 38 cases and malignant in 2 cases. Complications after surgery were seen in 3 cases. Although treatment requires total removal, in some cases require preoperative

源自头颈部脂肪组织:1例。预后目的:通过回顾一系列在北内大学医院(KUH)手术诊断的脂肪瘤的病例，明确其特点。方法:所有患者均于2000年1月至2021年12月行肿瘤切除术。通过病理科记录确定患者。结果:年龄2 ~ 80岁，平均年龄47.1岁。脂肪瘤为良性38例，恶性2例。所有38个脂肪瘤只需要手术。脂肪瘤3例术后出现并发症。在脂肪瘤的病例中，虽然术后结果不同，但没有复发。结论:回顾了40例患者的临床资料。脂肪瘤为良性38例，恶性2例。术后出现并发症3例。虽然治疗需要完全切除，但在某些情况下需要术前切除

引用次数: 0

Prevalence of Diabetes Insipidus and Other Complications in Early Period After Pituitary Surgery: Analysis of 259 Patients 垂体术后早期尿崩症及其他并发症259例分析

Biomedical Journal of Scientific & Technical Research

Pub Date : 2022-01-25 DOI: 10.26717/bjstr.2022.41.006581

E. Gormolysova

Eugeniya Galina Moisak. Prevalence of Diabetes Insipidus and Other Complications in Early Period After Pituitary Surgery: Analysis of 259 Patients. Biomed The purpose of this study was to describe complications associated with the endoscopic transsphenoidal approach and to determine a relation between postoperative central diabetes insipidus (DI) and the characteristics of adenomas. Methods: Results:

Eugeniya Galina Moisak。垂体术后早期尿崩症及其他并发症259例分析本研究的目的是描述内镜下经蝶窦入路相关的并发症，并确定术后中枢性尿崩症(DI)与腺瘤特征之间的关系。方法:结果:

引用次数: 1

Post-ACL Rupture Integrated Rehabilitative Pathway: Factors Influencing Economic Resources Absorption 前交叉韧带断裂后综合康复途径:影响经济资源吸收的因素

Biomedical Journal of Scientific & Technical Research

Pub Date : 2022-01-20 DOI: 10.26717/bjstr.2022.41.006564

L. Ferrario

To investigate the drivers that might influence the patient’s integrated rehabilitative pathway, after the rupture of the anterior cruciate ligament (ACL), in terms of economic resources absorption. Materials and Methods: An observational study, conducted in two private rehabilitation hospitals located in Italy, was conducted to obtain real-world data concerning the integrated rehabilitative pathway of 118 patients. Patients’ data were analysed adopting three methodological approaches. the predictors of the dependent variable. statistical approaches, comparative-configurational Results: Results reported that older age (β=0.145, p=0.049), higher sportiness level (β=0.169, p=0.022), as well as the length of the integrated rehabilitative pathway (β=0.550, p-value=0.000) and the performance of threshold tests (β=0.389, p-value =0.000) are antecedents of higher management costs (Adjusted R²=0.703 and F=24.482). Summarizing QCA results, age, and the level of sportiness of patients, in combination with the compliance, play an important role in the emergence of the selected and analyzed management costs. Conclusions: Findings could be useful for the optimization of integrated rehabilitative pathway, thus becoming more efficient and effective, guaranteeing a process personalization, consistent with efficiency-driven and cost-containment strategies.

从经济资源吸收的角度探讨前交叉韧带(ACL)断裂后影响患者综合康复路径的驱动因素。材料与方法:在意大利的两家私立康复医院进行了一项观察性研究，以获得118名患者的综合康复途径的真实数据。采用三种方法分析患者数据。因变量的预测因子。结果显示，老年(β=0.145, p=0.049)、高运动水平(β=0.169, p=0.022)、综合康复路径长度(β=0.550, p值=0.000)和阈值测试表现(β=0.389, p值=0.000)是高管理成本的前因(调整后R²=0.703,F=24.482)。总结QCA结果，患者的年龄和运动水平，结合依从性，在选择和分析管理成本的出现中起着重要作用。结论:研究结果可用于优化综合康复路径，从而提高效率和效果，保证过程个性化，符合效率驱动和成本控制策略。

{"title":"Post-ACL Rupture Integrated Rehabilitative Pathway: Factors Influencing Economic Resources Absorption","authors":"L. Ferrario","doi":"10.26717/bjstr.2022.41.006564","DOIUrl":"https://doi.org/10.26717/bjstr.2022.41.006564","url":null,"abstract":"To investigate the drivers that might influence the patient’s integrated rehabilitative pathway, after the rupture of the anterior cruciate ligament (ACL), in terms of economic resources absorption. Materials and Methods: An observational study, conducted in two private rehabilitation hospitals located in Italy, was conducted to obtain real-world data concerning the integrated rehabilitative pathway of 118 patients. Patients’ data were analysed adopting three methodological approaches. the predictors of the dependent variable. statistical approaches, comparative-configurational Results: Results reported that older age (β=0.145, p=0.049), higher sportiness level (β=0.169, p=0.022), as well as the length of the integrated rehabilitative pathway (β=0.550, p-value=0.000) and the performance of threshold tests (β=0.389, p-value =0.000) are antecedents of higher management costs (Adjusted R²=0.703 and F=24.482). Summarizing QCA results, age, and the level of sportiness of patients, in combination with the compliance, play an important role in the emergence of the selected and analyzed management costs. Conclusions: Findings could be useful for the optimization of integrated rehabilitative pathway, thus becoming more efficient and effective, guaranteeing a process personalization, consistent with efficiency-driven and cost-containment strategies.","PeriodicalId":9035,"journal":{"name":"Biomedical Journal of Scientific & Technical Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86833327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Biomedical Journal of Scientific & Technical Research

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀